[HTML] nih.gov

[HTML][HTML] Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management-HFrEF in the Ambulatory Setting

N Naser, M Kulić, Z Jatić - Medical Archives, 2022 - ncbi.nlm.nih.gov
Background: The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …
被引用次数：6 相关文章
[PDF] researchgate.net

[PDF][PDF] Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management-HFrEF in the Ambulatory Setting

N Naser, M Kulić, Z Jatić - researchgate.net
Background: The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …

Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management-HFrEF in the Ambulatory Setting

N Naser, M Kulić, Z Jatić - Medical archives (Sarajevo …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …

Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management-HFrEF in the Ambulatory Setting.

N Naser, M Kulić, Z Jatić - Medical Archives (Sarajevo, Bosnia and …, 2022 - europepmc.org
Background The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …
[PDF] semanticscholar.org

[PDF][PDF] Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management-HFrEF in the Ambulatory Setting

N Naser, M Kulić, Z Jatić - pdfs.semanticscholar.org
Background: The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …